Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q) ; volume:15 ; number:1 ; day:8 ; month:7 ; year:2015 ; pages:1-6 ; date:12.2015
BMC cancer ; 15, Heft 1 (8.7.2015), 1-6, 12.2015
- Urheber
-
Butrym, Aleksandra
- Beteiligte Personen und Organisationen
-
Lech-Maranda, Ewa
Patkowska, Elżbieta
Kumiega, Beata
Bieniaszewska, Maria
Mital, Andrzej
Mądry, Krzysztof
Torosian, Tigran
Wichary, Ryszard
Rybka, Justyna
Warzocha, Krzysztof
Mazur, Grzegorz
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1444-1
- URN
-
urn:nbn:de:1111-2016110617712
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Butrym, Aleksandra
- Lech-Maranda, Ewa
- Patkowska, Elżbieta
- Kumiega, Beata
- Bieniaszewska, Maria
- Mital, Andrzej
- Mądry, Krzysztof
- Torosian, Tigran
- Wichary, Ryszard
- Rybka, Justyna
- Warzocha, Krzysztof
- Mazur, Grzegorz
- SpringerLink (Online service)
Ähnliche Objekte (12)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)